<?xml version="1.0" encoding="UTF-8"?>
<p>JNJ-678 is a potent RSV-specific fusion inhibitor that has been shown to act as an effective anti-RSV 
 <italic>in vitro</italic> and in animal models (
 <xref rid="ref123" ref-type="bibr">Roymans et al., 2014</xref>; 
 <xref rid="ref2" ref-type="bibr">Ackermann et al., 2016</xref>). Clinical studies in healthy adults assessed its antiviral efficacy as well as safety. It was shown that JNJ-53718678 reduced RSV viral load, respiratory infectionsâ€™ severity caused by RSV, and duration of the disease (
 <xref rid="ref71" ref-type="bibr">Israel et al., 2016</xref>; 
 <xref rid="ref67" ref-type="bibr">Huntjens et al., 2017</xref>). Further studies are needed in infants and children to prove the antiviral activity of this anti-RSV candidate.
</p>
